High expression of the p53 isoform γ is associated with reduced progression-free survival in uterine serous carcinoma

Katharina Bischof1,2*, Stian Knappskog3,4, Ingunn Stefansson5,6, Emmet Martin McCormack1, Jone Trovik7,2, Henrica Maria Johanna Werner7,2, Kathrine Woie2, Bjorn Tore Gjertsen1,8 and Line Bjorge1,2

Abstract

Background: Uterine serous carcinoma (USC) is a rare but aggressive subtype of endometrial carcinoma. Large-scale comprehensive efforts have resulted in an improved molecular understanding of its pathogenesis, and the p53 pathway has been proposed as a key player and is potentially targetable. Here we attempt to further portray the p53 pathway in USC by assessing p53 isoform expression.

Methods: We applied quantitative Real-Time PCRs (RT-qPCR) for expression analyses of total p53 mRNA as well as quantitative distinction of p53β, p53γ, and the total mRNA of amino-terminal truncated Δ40p53 and Δ133p53 in a retrospective cohort of 37 patients with USC. TP53 mutation status was assessed by targeted massive parallel sequencing. Findings were correlated with clinical data.

Results: The p53 isoform expression landscape in USCs was heterogeneous and dominated by total Δ133p53, while the distinct p53β and p53γ variants were found at much lower levels. The isoform expression profiles varied between samples, while their expression was independent of TP53 mutation status. We found high relative p53γ expression to be associated with reduced progression-free survival (PFS).

Conclusions: This is the first indication that elevated p53γ expression is associated with reduced PFS in USC. This single-center study may offer some insight in the landscape of p53 isoform expression in USC, but further validation studies are crucial to understand the context-dependent and tissue-specific role of the p53 isoform network in gynecological cancer.

Keywords: Uterine serous carcinoma, Type II endometrial cancer, p53 isoforms, RT-qPCR, mRNA expression analysis, Biomarker

Background

Endometrial cancer is the most common gynecological malignancy in the Western world [1, 2], with the incidence increasing in recent years [3]. Traditionally, endometrial neoplasms are categorized into Type I and Type II cancers [4]. While the majority of tumors are classified as Type I, which are usually highly differentiated and thus less aggressive, around 20% of patients suffer from clinically aggressive Type II cancers that in a much higher percentage have extraterine spread at the time of diagnosis and account for the majority of cancer related deaths [4–6].

Through large-scale comprehensive molecular characterization, endometrial carcinomas have recently been classified into four specific subgroups and we have gained a new understanding of the biology of USC [7]. The serous subtype has been shown to molecularly resemble basal-like breast cancers as well as high-grade serous ovarian carcinomas [7]. In USC, somatic mutations in the TP53 gene are a common characteristic and seen in more than 90% of cases, resulting in genetic instability and widespread copy-number alterations. Although other subtype-specific molecular features are present, including increased transcriptional activity of genes such as CCNE1 or MYC, that are involved in cell cycle regulation...
[7], it has become increasingly clear that the p53 pathway may be a key player in the genesis of USCks [8].

Mutant p53 proteins have been shown not only to lose their tumor-suppressive functions but also to gain oncogenic traits [9]. Additionally, p53 function has recently been shown to be modulated by a number of alternative mechanisms through a network of structurally similar proteins in the p53 pathway [10, 11]. In TP53 wild-type USC, inactivation of the p53 pathway must occur through alternative cellular mechanisms.

High-throughput RNA sequencing has produced vast amounts of data showing that more than 90% of human protein-coding genes produce multiple mRNA isoforms through such posttranscriptional mechanisms as non-canonical splicing and the use of alternative promoters [12, 13]. In humans, at least 12 different protein-encoding transcripts from the TP53 locus have been reported; these are suggested to contain detectable, predictive, and prognostic markers to guide patient treatment in a large number of cancers [14]. The complex isoform composition limits the ability to quantitatively distinguish the amino-terminally truncated variants Δ40p53 and Δ133p53 into α, β, and γ. For the carboxy-terminal (C-terminal) altered variants p53β and p53y and the amino-terminally (N-terminally) truncated isoforms Δ40p53 and Δ133p53, mRNA expression levels have been shown to be associated with tumor characteristics and aggressiveness in other p53-disrupted malignancies, such as breast cancer and epithelial ovarian carcinoma among others [14].

In acute myeloid leukemia (AML), TP53 mutation represents a rare event. In this context, p53β and p53y protein isoforms have been shown to positively correlate with the NPM1 mutation marker for survival, overall survival and response to chemotherapy. [24] Thus, the highly abrogated p53 pathway may represent an attractive future therapeutic target [25, 26].

While the functional roles of p53 isoforms have been studied in the past both in vitro and in a number of clinical studies, to the best of our knowledge, a characterization of p53 isoform expression in USC tissue has never been reported. In this study, we present the mRNA expression analysis of the main p53 isoforms (the exon composition of relevant p53 isoforms is illustrated in Fig. 1b) in combination with TP53 mutational status in serous endometrial cancers. Although the field of p53 research is constantly producing new insights into p53 structure and function, we are the first to offer an overview of the p53 isoform expression profiles of the main p53 isoforms in combination with TP53 mutational status in serous endometrial cancers.

Methods

Patient characteristics and tumor specimens

Between June 2001 and April 2013, a total of 79 women were diagnosed with and treated for USC at Haukeland University Hospital, Bergen, Norway. For 37 of the patients, biological material for DNA sequencing and mRNA expression analysis was available together with prospectively collected clinicopathological data. The following parameters from our clinical database were relevant in this study: age at primary treatment, FIGO 2009 stage, level of complete cytoreduction and progression-free survival (PFS). PFS was defined as time in months from the last day of primary treatment to disease recurrence defined by RECIST criteria [27]. Women were followed for a mean of 35 months (range 2–113), with the last follow-up entry in April 2015.

Tumor samples were acquired from hysterectomy specimens or diagnostic biopsies and included in the Bergen Gynecologic Cancer Biobank (REK Vest: Reference ID: 2014/1907). After collection at the time of primary diagnosis, tumor tissue was immediately frozen in liquid nitrogen. The tumor content of fresh frozen specimens was assessed in ethanol-fixed and hematoxylin-eosin-stained sections. While the minimum cutoff for inclusion was set to 50%, tumor purity was above 80% in the majority of tissue samples studied. The histopathological analysis was performed at the Haukeland University Hospital, Department of Pathology. Specimens were fixed in buffered formaldehyde, embedded in paraffin and further processed in the laboratory before standard histological sections were made. Trained gynecologic pathologists performed the diagnostic assessments. This material has been reviewed previously [28].

Nucleic acid isolation and cDNA synthesis

DNA was isolated by tissue digestion overnight at 65°C in lysis buffer containing NaCl, EDTA 0.5 M pH 8.5,
TrisM pH 8, sodium dodecyl sulfate (SDS) 5%, proteinase K 20 mg/ml and H2O, followed by standard ethanol precipitation with sodium perchlorate and isopropanol. DNA quantity was determined using a Qubit Fluorometer (Thermo Fisher Scientific, Waltham, MA, United States of America). RNA was extracted using the RNaseasy Mini Kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions and quantified using a NanoDrop M-1000 Spectrophotometer (Thermo Fisher Scientific, Waltham, MA, United States of America) and Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, United States of America). Single-strand cDNA was synthesized from 500 ng total RNA in a 20 μL reaction mix, using the Transcriptor reverse transcriptase system (Roche, Basel, Switzerland) according to the manufacturer's protocol.

**Quantitative real-time PCR**
Quantitative PCRs (qPCR) were performed using specific primers and hydrolysis probes targeting *TP53* on a LightCycler 480 instrument (Roche, Basel, Switzerland). Reaction mixes were prepared using the LightCycler 480 ProbesMaster kit (Roche, Basel, Switzerland), according to the manufacturer's instructions. Relative mRNA expression levels of the p53 transcripts were normalized to an internal reference, *RPLP2* gene expression, amplified together with the p53 amplifications in a two-color duplex reaction. Primers/probes for detection of total p53, and mRNAs with the characteristic breakpoints for p53β, p53γ, Δ40p53 and Δ133p53, as well as *RPLP2* are listed in Additional file 1: Table S1; they were designed to be used under the same conditions in the qPCR amplification. All individual assays were validated on control DNA (plasmids) containing the specific isoform breakpoints and tested for cross-reactions against the other isoforms. Given this design, our assays for Δ40p53, Δ133p53 yielded data representing the total pool of molecules harboring these breakpoints, including both the canonical p53α and the p53β and p53γ forms in the exon 9–10 region. Our p53β and p53γ assays were specific for these breakpoints and included the different N-terminal isoforms. Thermocycling conditions for the qPCR were an initial denaturation step at 95 °C for 5 min, followed by 50 cycles of denaturation for 10 s at 95 °C and annealing / elongation at 53 °C for 20 s. Comparison between samples was performed using the ΔΔCt-method. Each analysis was performed in triplicate.

**TP53 mutation calling**
*TP53* mutation status was extracted from targeted massive parallel sequencing of tumor DNA. A total of 1000 ng of dsDNA was fragmented using the Covaris® M220 Focused-ultrasonicator™ (Covaris, Woburn, MA, United States of America). Library preparation was performed using the Agilent SureSelect XT-kit (Agilent Technologies, Santa Clara, CA, United States of America). All samples were run on a MiSeq instrument (Illumina, San Diego, CA, United States of America), and preliminary mutation calling was performed using the MiSeq reporter (MSR) software. From the raw mutation calling output, post-processing filters were applied and all suspected *TP53* mutations were validated by manual inspection of sequencing reads using the Integrative Genomics Viewer [29].

**Statistical analyses**
The Shapiro-Wilk test was applied to assess the normality assumption. As the distribution of total p53, Δ40p53, Δ133p53, p53β and p53γ was non-Gaussian, Spearman correlation was calculated for continuous variables and Mann-Whitney U test was used to identify correlations between continuous data (age, PFS, FIGO stage and isoform expression levels) and *TP53* mutation status, presence of complete cytoreduction or age grouped by median. Fisher's exact test was used for comparisons of categorical variables (patient age, presence of complete cytoreduction and mutation status). Multiple linear regression was used to assess whether confounding was present. Survival analyses were performed by the Kaplan-Meier method, and subsets of patients (divided by median relative expression of isoforms) were compared using the log-rank test. All p-values are two sided and p-values < 0.05 were considered significant. Statistical analyses were performed using the software package SPSS 22.0 (SPSS Inc., Chicago, IL, United States of America).

**Results**

**Patient characteristics**
A total of 37 patients diagnosed with USC were included. The mean and mode age at time of diagnosis was 74 and 73 years, respectively (range 56–88 years). The mean PFS was 14 months (range 0–96 months). A substantial number of patients were diagnosed in the early stages of the disease as 41% (15 of 37) and 8% (3 of 37) of the women presented with FIGO stage I and stage II, respectively. In 32% (12 of 37) of cases, the tumors were classified as stage III, while stage IV disease was diagnosed in 19% (7 of 37) of cases. Primary debulking surgery was performed in all but one woman, who was regarded as inoperable due to advanced age, reduced performance status and advanced disease. Complete cytoreduction was achieved in 72% (26 of 36) of the women undergoing surgery, while optimal debulking could not be accomplished in 28% (10 of 36) of cases. 62% (23 of 37) of patients were additionally treated with adjuvant platinum-containing chemotherapy (Table 1).
We assessed the expression levels of total p53 mRNA, the C-terminal truncated isoforms p53β and p53γ, and the N-terminal truncated variants Δ40p53 and Δ133p53 by Real-Time qPCR. Notably, our assays were splice site specific, as such, combinations of alternative variants in the C- and N-terminal (variants with multiple alternative splice sites) were not discriminated. The Δ133p53 variant was detected alone or in combination with other p53 isoforms in 97% (36/37) of samples. The carboxy-terminal isoforms p53β and p53γ could be identified in 78% (29/37) and 76% (28/37) of specimens, respectively. In our dataset, all but two samples that expressed p53γ also expressed p53β. Moreover, in 25 of the samples in which p53β was detectable, p53γ was also expressed. A total of 70% (26/37) of samples expressed the combination of p53β and p53γ as well as Δ133p53 mRNA.

The p53 isoform expression levels were found to vary considerably from patient to patient (Fig. 2a–d). The largest variability was observed for Δ133p53, where we detected a 149-fold difference between the highest and the lowest expressing samples. The p53β and p53γ isoforms showed a variability of 109-fold and 70-fold, respectively. While Δ133p53 consistently accounted for the majority of isoforms expressed, p53β constituted a maximum 4% of isoforms expressed, while p53γ only was detectable in very low concentrations (Fig. 2e).

The mRNA expression levels of the p53β, p53γ, and Δ133p53 isoforms were all significantly associated with total p53 expression levels and each other (Fig. 3). We found that the total p53 expression levels correlated with

### Table 1 Clinical-pathological characteristics of USC patients (n = 37)

| Clinical parameters                  | mean (range) |
|-------------------------------------|--------------|
| Age at diagnosis; in years          | 74 (56–88)   |
| Follow-up time; in months           | 35 (2–113)   |
| Progression-free interval; in months | 14 (0–96)   |
| FIGO 2009 stage                     |              |
| IA                                  | 5 (14%)      |
| IB                                  | 10 (27%)     |
| II                                  | 3 (8%)       |
| IIIA                                | 2 (5%)       |
| IIIC                                | 10 (27%)     |
| IVA                                 | 1 (3%)       |
| IVB                                 | 6 (16%)      |
| Level of surgical cytoreduction a   |              |
| Complete                            | 26 (72%)     |
| Residual disease                    | 10 (28%)     |
| Adjuvant chemotherapy               |              |
| Yes                                 | 23 (62%)     |
| No                                  | 14 (38%)     |

*aPrimary debulking surgery was performed on 36 out of 37 women

### Table 2 Overview over relative expression of p53 isoforms in individual patients together with progression free-survival

| Patient ID | Δ133p53ratio | p53βratio | p53γratio | Progression free-survival (months) |
|------------|--------------|-----------|-----------|-----------------------------------|
| 1          | 67.16        | 6.05      | .86       | 29                                |
| 2          | 19.17        | 4.90      | 0         | 0                                 |
| 3          | 187.50       | 17.35     | 0         | 0                                 |
| 4          | 19.87        | 0         | 0         | 14                                |
| 5          | 0            | 0         | 0         | 7                                 |
| 6          | 17.21        | 0         | 0         | 1                                 |
| 7          | 42.31        | 17.08     | .79       | 27.85                             |
| 8          | 234.46       | 0         | 0         | 14                                |
| 9          | 22.37        | 0         | 2.63      | 10                                |
| 10         | 5.16         | .79       | .57       | 5                                 |
| 11         | 9.47         | 6.35      | 0         | 58                                |
| 12         | 7.93         | 1.68      | .29       | 96                                |
| 13         | 2.81         | .27       | .45       | 25                                |
| 14         | 2.65         | .67       | .66       | 11                                |
| 15         | 4.60         | 3.23      | 1.02      | 11                                |
| 16         | 6.78         | 3.60      | 1.35      | 2                                 |
| 17         | 2.26         | 1.30      | .74       | 0                                 |
| 18         | 5.75         | 2.10      | .93       | 2                                 |
| 19         | 10.55        | 3.09      | 1.56      | 19                                |
| 20         | 28.51        | 1.48      | 2.14      | 0                                 |
| 21         | 28.63        | 18.59     | 7.90      | 1                                 |
| 22         | 19.20        | 2.52      | .54       | 31                                |
| 23         | 35.80        | 18.67     | 5.20      | 15                                |
| 24         | 33.33        | 2.89      | .34       | 43                                |
| 25         | 36.17        | 4.86      | 4.62      | 0                                 |
| 26         | 97.55        | 60.37     | 3.39      | 0                                 |
| 27         | 10.57        | 5.58      | 1.44      | 1                                 |
| 28         | 6.16         | .98       | .48       | 4                                 |
| 29         | 42.70        | 8.18      | 2.23      | 48                                |
| 30         | 10.28        | 4.42      | .61       | 28                                |
| 31         | 60.74        | 0         | 0         | 11                                |
| 32         | 38.58        | 5.87      | 2.71      | 0                                 |
| 33         | 10.13        | 2.66      | 2.23      | 0                                 |
| 34         | 85.68        | 0         | 0         | 11                                |
| 35         | 7.51         | 0         | 1.94      | 15                                |
| 36         | 25.74        | 7.85      | 1.64      | 6                                 |
| 37         | 32.86        | 13.85     | 6.09      | 0                                 |

mRNA expression patterns of p53 isoforms in USC

We assessed the expression levels of total p53 mRNA, the C-terminal truncated isoforms p53β and p53γ, and the N-terminal truncated variants Δ40p53 and Δ133p53 by Real-Time qPCR. Notably, our assays were splice site specific, as such, combinations of alternative variants in the C- and N-terminal (variants with multiple alternative splice sites) were not discriminated. The Δ133p53 variant was detected alone or in combination with other p53 isoforms in 97% (36/37) of samples. The carboxy-terminal isoforms p53β and p53γ could be identified in 78% (29/37) and 76% (28/37) of specimens, respectively. In our dataset, all but two samples that expressed p53γ also expressed p53β. Moreover, in 25 of the samples in which p53β was detectable, p53γ was also expressed. A total of 70% (26/37) of samples expressed the combination of p53β and p53γ as well as Δ133p53 mRNA. We were not able to detect expression of Δ40p53 mRNA in any cases. (for illustration see Table 2).

The p53 isoform expression levels were found to vary considerably from patient to patient (Fig. 2a–d). The largest variability was observed for Δ133p53, where we detected a 149-fold difference between the highest and the lowest expressing samples. The p53β and p53γ isoforms showed a variability of 109-fold and 70-fold, respectively. While Δ133p53 consistently accounted for the majority of isoforms expressed, p53β constituted a maximum 4% of isoforms expressed, while p53γ only was detectable in very low concentrations (Fig. 2e). The mRNA expression levels of the p53β, p53γ, and Δ133p53 isoforms were all significantly associated with total p53 expression levels and each other (Fig. 3). We found that the total p53 expression levels correlated with...
the levels of $\Delta 133p53$ ($R = 0.503$, $p = 0.002$), $p53\beta$ ($R = 0.652$, $p < 0.001$) and $p53\gamma$ ($R = 0.603$, $p < 0.001$) (Fig. 3a–c). In addition, the relative expression levels of $p53\beta$, $p53\gamma$ and $\Delta 133p53$ isoforms within the tumors were highly correlated with one another. Expression of $\Delta 133p53$ was significantly associated with $p53\beta$ ($R = 0.692$, $p < 0.001$) and $p53\gamma$ ($R = 0.452$, $p = 0.005$). The $p53\beta$ expression was linked with $p53\gamma$ mRNA levels ($R = 0.709$, $p < 0.001$) (Fig. 3d–f).

**TP53 mutation status in USC**

In order to stratify $p53$ isoform expression data for *TP53* mutational status, targeted sequencing was performed. We detected somatic mutations in the *TP53* gene in 27 out of 37 (73%) tumor samples (Table 3). Notably, we found two of the samples to harbor two mutations. The most frequent point mutation detected was R248Q, observed in three patients. Several other hot-spot mutations such as R175H and R273H, were observed. Total $p53$ expression levels ($p = 0.578$) as well as the splice variants $\Delta 133p53$ ($p = 0.448$), $p53\beta$ ($p = 0.489$) and $p53\gamma$ ($p = 0.853$) were all independent of *TP53* mutation status (Fig. 2a–d).

**Prediction of clinical features by $p53$ isoform expression**

We tested whether the expression patterns of $\Delta 133p53$, $p53\beta$ and $p53\gamma$ correlate with disease characteristics and identified a significant association between patient age and concentration of total $p53$ ($p = 0.031$). However, age was no longer significantly associated with expression of total $p53$ ($p = 0.295$) for multiple linear regression that...
introduced expression of the p53β, p53γ, and Δ133p53 isoforms as covariates. For the other p53 splice variants, no relationship was established between mRNA expression levels and age or relevant tumor traits, such as stage at primary diagnosis and tumor resectability. Relative expression levels of the p53γ isoform had an impact on time to relapse after primary treatment was completed. Our data showed that higher ratios of p53γ to total p53 were associated with shorter PFS (log-rank \(p = 0.036\)) as illustrated in Fig. 4. No such correlation was found for the Δ133p53 and p53β isoforms.

**Discussion**

Over the last decade, the description of splice variants of the \(TP53\) gene has dynamically reformed the p53 field, and p53 isoforms have emerged as possible active contributors in cancer formation and progression [30] We have previously described that p53β and p53γ protein expression correlates positively with overall survival, chemotherapy response and mutational markers for survival in the aggressive blood cancer AML [24] Leukemia in general has a low occurrence of \(TP53\) mutations. It was therefore interesting to examine whether the \(TP53\) mutation status. We found the mean PFS in patients with \(TP53\) wild-type cancers to be 18 months versus 15 months among women with tumors harboring mutated \(TP53\). However, this difference was not statistically significant (log-rank \(p = 0.399\)).

**Tp53 mutation status and clinical parameters**

Both the patient characteristics, such as age (\(p = 0.180\)) and the tumor features, such as FIGO stage at primary diagnosis (\(p = 0.271\)) and presence of complete cytoreduction in operated patients (\(p = 0.580\)), were independent of \(TP53\) mutation status. We found the mean PFS in patients with \(TP53\) wild-type cancers to be 18 months versus 15 months among women with tumors harboring mutated \(TP53\). However, this difference was not statistically significant (log-rank \(p = 0.399\)).
expression levels of p53β, p53γ, or other isoforms had a prognostic implication in tumors with a high frequency of TP53 mutations. A recent publication by Shen et al. showed not only that mRNA isoform variations are associated with clinical outcomes in TCGA breast cancer data, but also that alternative splicing-based survival predictors consistently outperform gene expression-based prognosticators [31].

The focus of the present study was to assess the role of p53 splice variants in USC in a well-defined cohort of patients by performing highly sensitive quantitative Real-Time PCR. We detected expression of p53 isoforms in 97% of cases and found that expression levels varied considerably from patient to patient. Specifically, we found that the expression levels of the p53 isoforms p53β, p53γ, and Δ133p53 were all associated with total p53 expression levels. Whether this indicates that isoform expression is merely a side product of general TP53 transcriptional activity in many patients remains unknown. Furthermore, we show that the relative expression of p53β, p53γ, and Δ133p53 isoforms within the tumors were highly correlated with one another, consistent with findings in breast cancer [16].

The total Δ133p53 levels constituted the majority of p53 isoforms expressed in USC, while the levels of p53β and p53γ were much lower. The differential expression of Δ133p53 in cancerous cells seems to be highly dependent on the originating tissue. While an overexpression of

| Patient ID | FIGO 2009 tumor stage | Mutation* | Amino acid change | Effect | Progression free survival (months) |
|------------|------------------------|-----------|-------------------|--------|----------------------------------|
| 1          | 1c                     | c-7577120C > T | R273H          | missense c | 29                              |
| 2          | 4b                     | c-7577097C > T | D281N          | missense b | 0                               |
| 3          | 4b                     | c-7577538C > T | R248Q          | missense c | 0                               |
| 4          | 1b                     | c-7577581A > G | Y234H          | missense b | 14                              |
| 5          | 3c                     | c-7578394 T > A | H179L          | missense b | 7                               |
| 6          | 2b                     | c-7577539G > A | R248W          | missense c | 1                               |
| 7          | 3c                     | c-7578239C > A | E204 a         | nonsense b | 3                               |
| 8          | 1c                     | c-7577120C > T | R273H          | missense c | 14                              |
| 9          | 1a                     | c-7577573G > T | Y236 a         | nonsense b | 10                              |
|           |                        | c-7578211C > A | R213L          | missense b |                                  |
| 10         | 3a                     | c-7577580 T > C | Y234C          | missense b | 5                               |
| 11         | 4b                     | c-7577539G > A | R248W          | missense c | 58                              |
| 12         | 1c                     | c-7577153C > A | G262 V         | missense b | 96                              |
| 13         | 3c                     | c-7577538C > T | R248Q          | missense c | 25                              |
| 14         | 3c                     | c-7578508C > T | C141Y          | missense b | 11                              |
| 15         | 1c                     | c-7578442 T > C | Y163C          | missense b | 11                              |
| 16         | 3c                     | c-7578406C > T | R175H          | missense c | 2                               |
| 17         | 4b                     | c-7577586A > T | I232N          | missense b | 0                               |
| 18         | 3c                     | c-7577538C > T | R248Q          | missense c | 2                               |
| 19         | 1a                     | c-7578406C > T | R175H          | missense c | 19                              |
| 21         | 2a                     | c-7579556ATCAA | frameshift      | frameshift | 1                              |
| 23         | 1b                     | c-7577535C > G | R249T          | missense b | 15                              |
| 25         | 4a                     | c-758272G > A | H193Y          | missense b | 0                               |
| 26         | 3c                     | c-7577121G > A | R273C          | missense b | 0                               |
| 31         | 3c                     | c-7577569GT | non-frameshift deletion | non-frameshift deletion | 11                              |
| 32         | 3c                     | c-7578190 T > C | Y220C | missense b | 0                               |
| 34         | 1a                     | c-7577141C > T | G266E          | missense b | 11                              |
| 35         | 3a                     | c-7577130A > G | F270 L | missense b | 15                              |

*Coordinates: GRCh37
*bMutation has been reported earlier in the IARC archive [33]
*c Hot-spot mutation region

---

Table 3 Overview over TP53 mutations observed in patients

Bischof et al. BMC Cancer (2018) 18:684
Δ133p53 is seen in gastrointestinal tumors compared to cancer precursors [11] or paracancerous tissue [23], Van den Berg et al. showed that Δ133p53 variants were downregulated in the early stages of clear cell renal carcinoma [22]. There are conflicting reports regarding the clinical impact of Δ133p53 expression. The Δ133p53 β-variant has recently been linked to increased tumor invasiveness and worse prognosis in a cohort of breast cancers [17], but higher Δ133p53 levels have also been linked to favorable prognosis in TP53 mutant advanced ovarian cancer [19]. No such clinical associations of Δ133p53 expression were observed in our cohort.

We did not detect expression of the Δ40p53 isoform in any of the patients. This finding contrasts with several other forms of cancer. In breast cancer, Δ40p53 has been found to be the main isoform expressed, and it is significantly upregulated when compared to benign breast tissues, particularly in triple negative breast tumors [16]. Hofstetter et al. showed the same significant upregulation of Δ40p53 in mucinous ovarian carcinomas in contrast to normal ovarian tissues and also indicated that higher expression of Δ40p53 constituted an independent prognosticator for longer PFS [20]. In renal cell carcinoma, Δ40p53 was also present and significantly upregulated in the advanced stages [22].

For the p53β isoform, Avery-Kiejda et al. [16] reported an association between lower expression levels and diminished metastasis-free survival and a significant negative association with tumor size in a series of breast cancers. In our data, no such effect was seen.

Although the number of patients included in our study is limited, our data strongly suggest that high relative expression of p53γ is associated with shorter PFS. These findings are in contrast to data from breast cancer patients, where expression of p53γ has been linked to good prognosis in TP53 mutant tumors [15] and to tumor grade in unselected breast cancers [16]. In vitro, p53γ has been shown to affect FLp53-dependent transactivation of Bax and is therefore believed to exert tumor-suppressive functions [10]. Furthermore, stable transfection of lung carcinoma cell lines with the p53β and p53γ isoforms has been shown to exert chemosensitizing effects. Unexpectedly, the same cells showed accelerated tumor growth when compared to null cells in an in vivo model [32]. Although p53γ was associated with shorter PFS and we observed a strong correlation between levels of p53γ and p53β, we could not establish an association between p53β and PFS.

Our data demonstrated that the TP53 mutation rate was 73%, which is somewhat lower than in other studies [7]. This is probably due to random chance and the small cohort size. The number of patients with wild-type TP53 was limited in our present study, but we found no indications that the expression levels of any of the three detected isoforms were associated with TP53 mutation status in the tumors. This independence of isoform expression from TP53 mutation status is in line with previous findings in ovarian carcinoma and breast cancer series [15, 17, 20]. In our correlation analysis, TP53 mutation status could not predict cancer progression.

These data in combination highlight that p53 function is complex and must be regarded as a result of the precise and tissue-specific balance between expressions within the p53 isoform network [14]. It may well be, that the expression levels of certain isoforms may be associated with poor prognosis in some forms of cancer and good prognosis in others. Our data indicate that this may be the case for p53γ. We believe that our findings can help direct further study of p53 isoform expression in USC by introducing a potential, clinically applicable biomarker for future validation in other cohorts.

Conclusions

The TP53 mutational profile by itself appears not to contain any prognostic information for patients in this cohort. This single-center study may offer some insight in the landscape of p53 isoform expression in USC and introduces p53γ as a possible predictor of progression-free survival. The tissue-specific and complex regulation of the individual p53 isoforms must be understood before p53 isoforms can serve as predictive or prognostic biomarkers or therapeutic targets in USCs.

Additional file

Additional file 1: Table S1. Primers and probes for qPCR (DOCX 14 kb)
Abbreviations

AML: Acute myeloid leukemia; Bax: Bcl-2-associated X protein; CCNE1: Cyclin E1 Gene; C-terminal: Carboxy-terminal; FIGO: The International Federation of Gynecology and Obstetrics; MYC: Myc proto-oncogene; N-terminal: Amino-terminal; PFS: Progression-free survival; RECIST: Response evaluation criteria in solid tumors; RPLP2: Ribosomal protein lateral stalk subunit P2; RT-qPCR: Quantitative real-time PCR; TCGA: The cancer genome atlas; TP53: Tumor protein p53; USC: Uterine serous carcinoma

Acknowledgements

We thank Britt Irene Edvardsen, Reidun Kopperud, Kadri Madissoo and Beryl Leivaa for technical assistance.

Funding

This work was supported by grants from “The Western Norway regional Health Authority” (Project No. 911809 and 911852). The funding sources had no involvement in study design, collection of data, and analysis and interpretation of data. The writing of the report has not been influenced by the supporting institutions.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors’ contributions

KB, SK, BTG and LB conceived experiments. KB and SK carried out experiments and analysed data. KB created figures. IS, JT, HMJW and KW for molecularly enhanced chemotherapy to achieve synthetic lethality in endometrial tumors with mutant p53. Obstet Gynecol Int 2013; 2013: 624165. DOI: https://doi.org/10.1155/2013/624165.

Brosh R, Rotter V. When mutants gain new powers: news from the mutant p53 field. Nat Rev Cancer. 2009;9(10):701–13. https://doi.org/10.1038/nrc2693.

Marcel V, Fernandes K, Terrier O, Lane DP, Bourdon JC. Modulation of p53beta and p53gamma expression by regulating the alternative splicing of TP53 gene modifies cellular response. Cell Death Differ. 2014;21(9):1377–87. https://doi.org/10.1038/cdd.2014.73.

Fujita K, Mondal AM, Horikawa I, Nguyen GH, Kumamoto K, Sohn JJ, Bowman ED, Mathe EA, Schetter AJ, Pine SR, JH, Hoy J, Vitojsbek B, Bourdon JC, Lane DP, Harris CC. p53 isoforms Delta133p53 and p53beta are endogenous regulators of replicative cellular senescence. Nat Cell Biol. 2009;11(9):1135–42. https://doi.org/10.1038/ncb1928.

Scotti MM, Swanson MS. RNA mis-splicing in disease. Nat Rev Genet. 2016;17(1):19–32. https://doi.org/10.1038/nrg.2015.3.

Sibley CR, Blazquez L, Ule J. Lessons from non-canonical splicing. Nat Rev Genet. 2016;17(7):407–21. https://doi.org/10.1038/nrg.2016.46.

Surget S, Khoury MP, Bourdon JC. Uncovering the role of p53 splice variants in human malignancy: a clinical perspective. Onco Targets Ther. 2013;5:75–68. https://doi.org/10.2147/OTT.S38576.

Bourdon JC, Khoury MP, Diot A, Baker L, Fernandez K, Asubala M, Quinlan P, Purdie CA, Thompson AM. p53 mutant breast cancer patients expressing p53gamma have as good a prognosis as wild-type p53 breast cancer patients. Breast Cancer Res. 2011;13(1):R7. https://doi.org/10.1186/bcr2811.

Avery-Kiejda KA, Morten B, Wong-Brown MW, Mathe A, Scott RJ. The relative mRNA expression of p53 isoforms in breast cancer is associated with clinical features and outcome. Carcinogenesis. 2014;35(5):858–96. https://doi.org/10.1093/carcin/bgt411.

Gadea G, Argic N, Fernandes K, Diot A, Jorou SM, Abdallah S, Meuray V, Vinot S, Anguille C, Remenyi J, Khoury MP, Quinlan PR, Purdie CA, Jordan LB, Fuller-Pace FV, de Toledo M, Cren M, Thompson AM, Bourdon JC, Roux P. TP53 drives invasion through expression of its Delta133p53beta variant. elife. 2016;5 https://doi.org/10.7554/elif.e14794.

Hofstetter G, Berger A, Fiegl H, Slade N, Zoric A, Holzer B, Schuster E, Mobus VJ, Reimer D, Daxenbichler G, Marth C, Zeimet AG, Concin N, Zeillinger R. Alternative splicing of p53 and p73: the novel p53 splice variant p53delta is an independent prognostic marker in ovarian cancer. Oncogene. 2010;29(13):1997–2004. https://doi.org/10.1038/onc.2009.482.

Hofstetter G, Berger A, Schuster E, Wolf A, Hager G, Vergote I, Cadron I, Sehouli J, Braicu EI, Mahner S, Speiser P, Marth C, Zeimet AG, Ulmer H, Zeillinger R, Concin N. Delta133p53 is an independent prognostic marker in p53 mutant advanced serous ovarian cancer. Br J Cancer. 2011;105(10):1593–9. https://doi.org/10.1038/bjc.2011.433.

Hofstetter G, Berger A, Berger R, Zoric A, Braicu B, Reimer D, Fiegl H, Marth C, Zeimet AG, Ulmer H, Moll U, Zeillinger R, Concin N. The N-terminally truncated p53 isoform Delta40p53 influences prognosis in mucinous ovarian cancer. Int J Gynecol Cancer. 2012;22(3):372–9. https://doi.org/10.1097/IGC.0b013e31823ca031.

Marabese M, Marchini S, Marrazo E, Mariani P, Cattaneo D, Fossati R, Compagnoni A, Signorelli M, Moll U, Codegoni AM, Broggiini M. Expression levels of p53 and p73 isoforms in stage I and stage III ovarian cancer. Eur J Cancer. 2008;44(1):131–41. https://doi.org/10.1016/j.ejca.2007.10.011.
22. van den Berg L, Segun AD, Mensch S, Blasberg N, Grinstein E, Wai D, Anlauf M, Gabbert HE, Mahotka C, Heikaus S. Regulation of p53 isoform expression in renal cell carcinoma. Front Biosci. 2010;2:1042–53. PMID: 20515774

23. Ji W, Zhang N, Zhang H, Ma J, Zhong H, Jiao J, Gao Z. Expression of p53β and Δ133p53 isoforms in different gastric tissues. Int J Clin Exp Pathol. 2015;8(9):10468–74. PMCID: PMC4637571

24. Anensen N, Hjelle SM, Van Belle W, Haaland I, Silden E, Bourdon JC, Houland R, Tasken K, Knappskog S, Lonneng PE, Bruserud O, Gjertsen BT. Correlation analysis of p53 protein isoforms with NPM1/FLT3 mutations and therapy response in acute myeloid leukemia. Oncogene. 2012;31(12):1533–45. https://doi.org/10.1038/onc.2011.348.

25. Edmondson RJ, Crosbie EJ, Nickalloo-Amiry M, Kaufmann A, Stelloo E, Nijman HW, Leary A, Auguste A, Mileshkin L, Pollock P, MacKay HJ, Powell ME, Bosse T, Cruyssberg CL, Kitchener HC. Markers of the p53 pathway further refine molecular profiling in high-risk endometrial cancer: a TransPORTEC initiative. Gynecol Oncol. 2017;146(2):327–33. https://doi.org/10.1016/j.ygyno.2017.05.014.

26. Fransson A, Glässgen D, Alfredsson J, Wiman KG, Bagalica-Lagercrantz S, Mohell N. Strong synergy with APR-246 and DNA-damaging drugs in primary cancer cells from patients with TP53 mutant high-grade serous ovarian cancer. J Ovarian Res. 2016;9(1):27. https://doi.org/10.1186/s13048-016-0239-6.

27. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Danchev J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–47. https://doi.org/10.1016/j.ejca.2008.10.026.

28. Stefansson IM, Raeder M, Wilk E, Mannequint M, Kusminsko K, Knutsveg G, Haldersen I, Trovik J, Øyan AM, Kalland KH, Staff AC, Salvesen HB, Akslen LA. Increased angiogenesis is associated with a 32-gene expression signature and 6p21 amplification in aggressive endometrial cancer. Oncotarget. 2015;6(12):10634–45. https://doi.org/10.18632/oncotarget.3521.

29. Robinson JT, Thorvalsdottir H, Winckler W, Gutmann M, Lander ES, Getz G, Mesirov JP. Integrative genomics viewer. Nat Biotechnol. 2011;29(1):24–6. https://doi.org/10.1038/nbt.1754.

30. Mehta S, Tsai P, Lasham A, Campbell H, Reddel R, Braithwaite A, Print CA. Study of TP53 RNA splicing illustrates pitfalls of RNA-seq methodology. Cancer Res. 2016;76(24):7151–9.

31. Shen S, Wang Y, Wang C, Wu YN, Xing Y. SURVIV for survival analysis of mRNA isoform variation. Nat Commun. 2016;7:11548. https://doi.org/10.1038/ncomms11548.

32. Silden E, Hjelle SM, Wergeland L, Sulen A, Andresen V, Bourdon JC, Micklem DR, McCormack E, Gjertsen BT. Expression of TP53 isoforms p53beta and p53gamma enhances chemosensitivity in TP53(null) cell lines. PloS One. 2013;8(2):e56276. https://doi.org/10.1371/journal.pone.0056276.

33. Bousouin L, Sonkin D, Ardin M, Hollstein M, Byme G, Zavadil J, Olivier M. TP53 variations in human cancers: new lessons from the IARC TP53 database and genomics data. Hum Mutat. 2016;37(9):865–7. https://doi.org/10.1002/humu.23035.